CME Group (CME) Expands Its Product Suite, Is The Stock Cheap?
CME Group (CME) has just outlined a cluster of new products, led by the planned Treasury Link platform that connects U.S. Treasury futures and cash markets and gives investors fresh context for thinking about the stock.
See our latest analysis for CME Group.
Despite a steady flow of new products, CME Group’s recent share price performance has been weak, with the stock down about 10.9% year to date and the 30 day share price return down 10.86%. At the same time, the 3 year total shareholder return of 46.79% and 5 year total shareholder return of 41.60% point to a stronger longer term picture.
If these product launches have you thinking about where else growth and risk management themes are playing out, this could be a good time to check out 18 top founder-led companies
CME Group now sits about 11% lower for the year even as new products keep rolling out, so does that recent pullback leave the stock offering a reasonable trade off between risk and potential reward at today’s valuation?
Most Popular Narrative: 16.9% Undervalued
The most followed narrative currently places CME Group's fair value at $289, compared with a last close of $240.27, and grounds that view in detailed volume, product, and margin assumptions rather than short term price moves.
The ongoing global shift toward electronic trading, greater regulatory demands for transparency and standardized clearing, and a proven ability to grow non-transactional revenue (e.g., record market data revenue) position CME to capture a larger share of trading activity and support durable long-term earnings growth.
Want to understand why a higher fair value still uses a relatively moderate earnings multiple and tempered growth outlook? The narrative leans on steady revenue expansion, firm but slightly lower margins, and a specific timeline for earnings and share count changes. Curious how those ingredients combine into that $289 figure and discount rate assumption? The full story joins all of those moving parts together.
Result: Fair Value of $289 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the CME Group narrative still faces pressure from potential competition in perpetual futures, as well as the risk that lower volatility could soften trading volumes and fee revenue.
Find out about the key risks to this CME Group narrative.
Next Steps
If the mixed signals around CME Group have you on the fence, do not wait too long to weigh up both sides. Decide where you stand by checking the 3 key rewards and 2 important warning signs
Looking for more CME Group style investment ideas?
Do not stop your research with CME Group alone, broaden your watchlist now so you are not looking back later wishing you had acted sooner.
- Target potential mispricings by scanning a focused set of companies that currently screen as 45 high quality undervalued stocks.
- Strengthen the defensive side of your portfolio by reviewing companies highlighted in the 78 resilient stocks with low risk scores.
- Get ahead of the crowd by checking out the screener containing 19 high quality undiscovered gems before they attract wider attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com